[Market access agreements: Definition and features. Could MAA be defined as a solution for immunotherapy funding by French health system?].

Over the last few years, many therapeutic innovations have been approved and marketed in France, within a strained financial setting. Legal dispositions allowed manufacturers (LEEM - les enterprises du medicament) and the economic committee for health products (CEPS) to contract various confidential market access agreements to contain health product expenses. The purposes of this article are to define and describe these different existing market access agreements and to open discussion on their applicability to the problematic of immune-oncology drugs financing.

[Impact of the expiry of the patent on quality and price of medicines at hospital: Study of five anticancer drugs from 2008 to 2015 at the Assistance publique-Hôpitaux de Paris].

Objectives: Anticancer drugs were in 2005 the first expenditure item of the hospital drugs. Ten years later, it is noted that the placing on the market of generic drugs has led to a strong decrease of their price. To determine whether this decrease comes at the expense of product quality, a price-quality ratio trend study of five anticancer drugs was performed at AP-HP.

[Advances in the contributions of imaging to stereotaxic localization of cerebral arteriovenous malformations for radiosurgery ].

Historically, angiography was one of the first diagnostic methods to allow for visualization of neurovascular structures. It has been and still is very useful for precise evaluation of vascular pathology and is one of the main elements in treatment planning for radiosurgical targets. It is the only imaging method that gives insight into the angioarchitecture of a cerebral arteriovenous malformation, possibly reducing the target volume.

[Hodgkin's disease in children. Stage IV. Treatment and results].

Without prior treatment, 13 children with stage IV Hodgkin's disease have received a multiple drug therapy (MOPP). Of these patients, 7 have experienced a complete remission; 3 a partial remission, completed in two cases by radiotherapy on the site of the residual disease, and the third by another combination chemotherapy. Out of the 10 children living as of July 1st 1975, 8 are still on first remission.